Wipo Regional Workshop on Patent Analytics WIPO INPI

Wipo Regional Workshop on Patent Analytics ü WIPO & INPI ü Rio de Janeiro, August 26 a 28, 2013 ü Samples of Patent Analytics ü Observatory of Tecnologies - INPI/ Brazil ü Prof. Adelaide Antunes ü aantunes@inpi. ufrj. br OBTEC

OBTEC / INPI Observatory of Technologies Strategic utilization of IP System in favor of the economic development. Created in 2010, the Observatory stimulates the interaction between Brazilian Office and the several stakeholders of the Brazilian National Innovation System (Universities, Research Institutes, Finance Organizations, Government Agencies) OBTEC

Wipo Regional Workshop on Patent Analytics Observatory of Tecnologies - INPI/ Brazil It´s necessary University (papers) ü to identify the needs ü To develop a Strategy ü To search for information ü To analyse INPI (Government) Reports (patents) Industries Innovation ü To disseminate Economic Development OBTEC

COOPERATION AGREEMENT Partnership INPI – OBTEC / FINEP (Funding Authority for Studies and Projects) Observatory in the Health Sector üFINEP –goal: Introduce IP Culture üBrands / Patents OBTEC

EX. : EMS üPatents Priority Country Brazil Great Britain Patent Documents 7 3 Major Generic Drug Company (80% incoming) üTrademarks Sector Trademarks (applications) Pending applications Registered trademarks Dead trademarks Frist Application Latest Application Drugs 938 237 453 248 Nov. , 1963 June, 2012 Company EMS OBTEC

STUDIES - DRUGS- FINEP 1 2 3 4 5 6 Capítulo da NCM 3004. 90. 68 3004. 90. 69 3004. 39. 27 3004. 90. 99 3004. 90. 68 3004. 31. 00 Grupo I - Tipo i Medicamentos a base dos fármacos Atazanavir Ganciclovir Gosserelina Hidroxiuréia Indinavir Sulfato Insulina 7 3004. 90. 99 Isoniazida/Rifampicina/Pirazinamida/Etambutol 8 3004. 39. 81 Levotiroxina 9 3004. 90. 39 Mitoxantrona 10 3004. 90. 42 Talidomida Regra de origem: salto de posição tarifária, exceto do capítulo 30 OBTEC

Ganciclovir ü RN: 82410 -32 -0 ü IUPAC: 2 -amino-1, 9 -dihydro-9 -[[2 -hydroxy-1(hydroxymethyl)ethoxy]methyl]-6 H-Purin-6 -one ü Therapeutic class: antiviral ü Names and brands ü 2 -Amino-1, 9 -[[2 -hydroxy-1 -(hydroxymethyl)ethoxy]methyl]6 H-purin-6 -one ü Biolf 62 ü BN-B 759 V ü Gansikloviiri ü Gansiklovir ü Gancyclovir ü Gancyklovir ü Ganecicilovir ü Gansikloviiri ü Gansiklovir ü HSDB 6512 OBTEC

Ganciclovir ü Labs Brasil (DEF) Producers(DWCP) – 38 § Roche § China - 24 § Halex Istar § Índia - 4 § Blausiegel § Alemanha - 3 § Lafepe § Estados Unidos - 2 § Eurofarma § Argentina, Brasil, Canadá, França, Itália – 1 N º Priority documents / Country China - 18 EUA - 5 Índia - 5 Escritório Europeu de Patentes - 2 (Itália e França) Espanha e a Itália - 1 depósito cada. OBTEC

COOPERATION AGREEMENT Partnership INPI – OBTEC / FIOCRUZ Oswaldo Cruz Foundation Science at Service of Life Observatory in the Health Sector OBTEC

Partnership INPI (OBTEC) / FIOCRUZ ü to identify global trends in cancer § subsidize decision-making processes in the Brazilian healthcare sector Definition of (Brazilian) priorities üImportant to know the Patent landscape on cancer drugs § not-patented technologies § patents that have expired OBTEC

Partnership INPI (OBTEC) / FIOCRUZ Derwent Innovations Index 84. 351 patent documents related to cancer drugs (worldwide) OBTEC

STUDIES OBTEC

Scientific journal call for papers: International Journal of Molecular Sciences (2013) Trends in Nanopharmaceutical Patents Case Study Adelaide Antunes 1, Iolanda Fierro 1, Rafaela Guerrante 1, Flavia Mendes 2 and Maria Simone de M. Alencar 3 1 INPI; 2 UFRJ ; 3 FIOCRUZ OBTEC

Methodology ü Data Base Derwent Innovations Index Main Advantages § The summaries are full of keywords § The possibility of exporting the patent documents recovered in the search using software (Vantage Point) § The availability of Manual Code related to nanotechnology (classification attributed in the database to all patent documents indexed in it) ü Selection of documents that were indexed between 2002 and 2012 in the Derwent database OBTEC

Manual Codes related to nanotechnology applied to the pharmaceutical sector, and the number of patent documents Derwent manual code B 12 -M 11 Q B 12 -M 10 A 7 B 11 -C 12 B 05 -U 05 A B 05 -U 05 B Description Nanoparticles Nanotechnology devices Nanotechnology (general) Nanotubes, nanorods or nanohorns nanofilms B 05 -U 05 C Nanostructures, other than those covered by B 05 -U 05 A and B 05 -U 05 B B 05 -U 05 B 05 -U 04 B 05 -U 03 Other carbon containing 3 -D structures Carbon plus heteroatom nanotubes Carbon-only nanotubes Number of patent documents 2, 306 160 5, 028 100 44 40 615 Focus on Special Issue “Bioactive Nanoparticle 2012” toxicity and nanoparticle nano-imaging agent nanoparticle for drug delivery cancer-targeting nanoparticle Removing the patent document that were in more than one of the nine series OBTEC

Results OBTEC

The main patent applicant by area Total of patents Entity applying for patents Toxicity of nanoparticle Nanoimaging agent Nanoparticle for drug delivery Cancertargeting nanoparticle 23 Univ. of California 7 9 21 Massachusetts Inst. Technology 8 5 7 11 20 General Electric Co 10 20 0 0 16 Univ. Nat. Tsing Hua 0 0 12 0 15 GP Medical Inc. 0 0 11 0 12 Univ. Texas System 0 6 5 6 8 Univ. Northwestern 0 0 0 6 8 Elan Pharma Int. Ltd 7 0 0 0 8 Konink Philips Electronics NV 0 8 0 0 7 Centre National de La Recherche Scientifique (CNRS) 7 0 0 5 7 Abraxis Bioscience LLC 7 0 0 0 7 Fuji Film Co Ltd 0 0 6 Brigham & Women’s Hospital Inc. 0 0 0 6 5 Univ. Kyushu 0 0 5 0 OBTEC

MIT Partnerships ü MIT § nanoparticles for use in encapsulating a biologically active agent (e. g. , polynucleotide) Advantage is in effectively providing low immunogenicity and toxicity Universities and Hospitals OBTEC

Rethinking The Conceptual Base For New Practical Applications In The Information Value And Quality (IGI Global 2014 USA) Chapter 5 - The Contribution of Information Science through Intellectual Property to Innovation in the Brazilian Health Sector Adelaide Maria de Souza Antunes, Flavia Maria Lins Mendes, Suzanne de Oliveira Rodrigues Schumacher, Luc Quoniam, Jorge Lima de Magalhães OBTEC

Brazil Health System (SUS) ü Section 1: Pharmaceuticals industry, made up of six groups § Group 1 – Antivirals (including antiretrovirals) § Group 2 – Neglected Diseases § Group 3 – Chronic non-communicable diseases § Group 4 – Biological pathways § Group 5 – Vaccines and Hemoderivatives § Group 6 – Medications and inputs for the treatment of medical issues resulting from nuclear accidents. ü Section 2: Medical devices and healthcare devices in general OBTEC

Methodology ü Database used to access the patent documents: Sci. Finder Scholar ü Search for each drug, using the CAS Registry Number ü Informations § patents relating to processes (synthesis and/or formulation); § main Applicants (assignees) § top countries § information about the first patent for the drug, date and respective assignee § patents filed in Brazil § trends over time of patenting OBTEC

Atorvastatin ü Atorvastatin (CAS RN: 134523 -00 -5) ü 114 process patents § 84 are for its synthesis § 26 for its formulation § 4 for its synthesis and formulation ü Companies with the most patents (eight each) § Teva Pharmaceuticals Industries § Warner-Lambert Company ü First patent § 1986 Warner-Lambert Company ü Brazil (17 deposits) § Warner Lambert Company (five for synthesis and one formulation) § Teva Pharmaceuticals Industries (one formulation and one for synthesis) § Pfizer (synthesis) OBTEC

Calcitonin ü Calcitonin (CAS RN: 9007 -12 -9) ü 204 process patents § 169 are for its synthesis § 28 for its formulation § 7 for its synthesis and formulation ü Companies with the most patents § Armour Pharmaceutical (USA) - 9 ü First patent § 1968 Ciba Ltd (Switzerland) ü Brazil (10 patents) § 2 for synthesis by Institut Gustave Roussy (France), OBTEC

Scientific journal III Academic Intelectual Property and Innovation Development Meeting ( III ENAPID - INPI 2010) Key Structures on Synthesis of HIV drugs Adelaide Maria de Souza Antunes 1, Rodrigo José Ávila Cartaxo 2, Flavia Maria Lins Mendes 2 1 INPI; 2 UFRJ OBTEC

19 HIV / Sci. Finder (CAS/ACS) Busca: RN Top Applicants: Merck & Co - 15 patentes Bristol-Myers Squibb Co - 10 patentes Technology domination: 54% em PCT EUA – 40% China, Índia e Japan – 41% OBTEC

Methodology – 19 HIV OBTEC

KEY Chemical Substances Analysis for HIVs 5 -METHYLURIDINE Zidovudine Estavudine 2 routes 4 routes Bristol-Myers (US) and Ajinomoto (JP) Bristol-Myers, Ajinomoto, Japan Tobacco and China Pharmacy Univ 24 producers : 16 China, 2 Canada, 2 USA, 1 Italy, 1 Korea, 1 Slovakia and 1 Rússia OBTEC

Mapping technological knowlodge of ethanol 2º Generation Thesis Luiz André Felizardo S. Schlittler (EQ/UFRJ) Advisers: Prof. Nei Pereira Jr. / Profa. Adelaide Antunes(INPI) OBTEC

Produção de etanol 2 G Enzymatic hydrolysis Technological focus Genetic modification micro-organims Midwest R. Inst. Univ. Florida Enzyme production Others compounds production OBTEC

Technological Foresight applied nanotechnology Thesis Maria Simone de Menezes Alencar (EQ/UFRJ) Adviser: Adelaide Maria de Souza Antunes (INPI) OBTEC

THERMS (strategy) ü Base de dados: Derwent Innovation Index OBTEC

Results § Top countries OBTEC

Analysis OBTEC

Patenting in The US NANOPRODUCTUS: radiografia industrial, sistemas óticos e de imagem NANOINTERMEDIATES: biosensores, dispositivos fotovoltaicos e para armazenamento de memória CLUSTER 1 NANOPRODUCTUS : com aplicações em computadores, filmes e automóveis NANOPRODUCTUS dentais, adesivos e revestimentos dentais e equipamentos ortodônticos. OBTEC

Agriculture Innovation Strategy and Technology in Seeds Estratégia de Inovação e Tecnologia em Sementes. Thesis Rafaela Guerrante (EQ/UFRJ) advisers: Prof. Nei Pereira Jr. e Profa. Adelaide Maria de Souza Antunes OBTEC

Case Study – Monsanto’s patents on GURT (genetic use restriction technology) ü GURT technology § colloquially known as terminator/traitor technology § causes second generation seeds to be sterile Terminator § the use of an external chemical inducer which turns "on or off" a plant's genetic traits (ex. sterility) Traitor ü There are not specific keywords/IPCs to describe GURT technology ü 1224 Monsanto’s patent documents were retrieved, possibly related to GURT ü In order to validate the results and analyze the technologies described in the patents retrieved, a methodology was developed. OBTEC

Methodology 1 st step Reading of TITLE and/or ABSTRACT Reading of CLAIMS and/or DESCRIPTION OBTEC

Methodology 2 st step Terminator 779 documents “herbicide tolerance” Filter using AND/OR “pest resistance” “increased grain yield” “tolerance to” “increased growth rate” DISCARD 14 documents 765 documents “resistance to” NOT RELATED Reading of CLAIMS and DESCRIPTION Filter - (“sterility” OR “sterile”) ANDmale DO NOT CONTAIN(“sterility” OR“sterile”) AND male 756 documents 9 documents 8 documents 764 docs. related to MALE-STERILITY + Reading of CLAIMS and DESCRIPTION 1 doc. NOT RELATED OBTEC

Patent and Publications Networks related to Dengue and HPV vaccines: its implications for policy of innovation in health Thesis Priscila Rohem-Santos (IE/UFRJ) Advisor: Claudia Inês Chamas OBTEC

Survey design and data sources / Analysis The search strategy encompasses definition of : § keywords § IPC and Derwent Manual codes § database The methodology of analysis involves: I – Identification of Dengue and HPV vaccine patent applications and articles; II – Creation of clusters according to various indicators such as applicant, priority number, validity (legal status); III – Claims' analysis of the applications filed in Brazil. IV – Social Network analysis (coauthorsip/ corinventorship) OBTEC

Survey design and data sources / Analysis (3 databases for articles) (3 databases for patents) Merge results of diferent databases Harmonization of names – Thesaurus Ex. : merges/acquisition of pharamautical industries considering the vaccine sector (Aventis Pasteur + Pasteur Meriex Connaugth = Aventis Pasteur (Sanofi) + Panacea + Shanta = Sanofi Pasteur (Homma et al, 2011) Removal of duplicates Adjacency matrices – correlation of data OBTEC

RESULTS: HPV articles and patents networks BR OBTEC

RESULTS: Dengue articles and patents networks Fragility of brazilian researchers’ conection BR OBTEC

Thanks!!! Adelaide Antunes aantunes@inpi. gov. br Elaine Vianna elainev@inpi. gov. br Bernanrdo. Nunes bernardo. nunes@inpi. gov. br Cristina D’Urso cmendes@inpi. gov. br Priscila Rohem prirohem@inpi. gov. br Rafaela Guerrante rafaela@inpi. gov. br obtec@inpi. gov. br OBTEC